For research and educational purposes only. Not medical advice.
LL-37 Reference
Educational, not medical advice reference for LL-37: Immune, Recovery; regulatory status, evidence posture, source review, and schedule notes. A…
Reference summary
Published literature is dominated by antimicrobial, chemotactic, and wound-healing research across in vitro, ex vivo, and small translational studies. Direct human clinical efficacy evidence for LL-37 as a standalone therapy is limited.
Regulatory and posture
- Categories
- Immune, Recovery
- Aliases
- Cathelicidin LL-37, hCAP18 C-terminal fragment, CAP-18 (104-140)
- Evidence posture
- preclinical - Mostly in vitro, ex vivo, and animal data. Human clinical evidence for LL-37 as a standalone therapy is limited.
- Regulatory status
- No FDA-approved LL-37 drug label. LL-37 is the mature antimicrobial cathelicidin fragment studied for antimicrobial, immune-modulation, and wound-healing roles, mostly in preclinical and translational work.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: Vandamme 2012 comprehensive summary of LL-37 cathelicidin peptide (Cell Immunol)
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.